CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1, Open-Label, Multiple-Ascending Dose Study of the Safety and Tolerability of CTX-471 Administered Either as a Monotherapy or in Combination With Pembrolizumab in Patients With Inadequate Responses to PD-1/PD-L1 Checkpoint Inhibitors in Metastatic or Locally Advanced Malignancies

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03881488
Title field or adapter rule: {'original_value': 'A Phase 1, Open-Label, Multiple-Ascending Dose Study of the Safety and Tolerability of CTX-471 Administered Either as a Monotherapy or in Combination With Pembrolizumab in Patients With Inadequate Responses to PD-1/PD-L1 Checkpoint Inhibitors in Metastatic or Locally Advanced Malignancies', 'source_field': 'protocolSection.identificationModule.officialTitle'}
Ingested At: 2026-10-30T23:06:05.296706+00:00
Published At: 2026-10-09T00:00:00+00:00
Record Updated At: 2026-10-09
Results Posted At: 2026-10-09
Source Retrieved At: 2026-10-30T22:07:52.791150+00:00
Timestamp Basis: ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter
Date limitation: ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

protocolSection.conditionsModule.conditions: ["Locally Advanced Solid Tumor", "Metastatic Cancer", "Non-small Cell Lung Cancer", "Small Cell Lung Cancer", "Mesothelioma", "Melanoma", "Head and Neck Cancer"]
protocolSection.statusModule.lastUpdatePostDateStruct: {"date": "2026-10-09", "type": "ACTUAL"}
protocolSection.identificationModule.nctId: "NCT03881488"
protocolSection.identificationModule.officialTitle: "A Phase 1, Open-Label, Multiple-Ascending Dose Study of the Safety and Tolerability of CTX-471 Administered Either as a Monotherapy or in Combination With Pembrolizumab in Patients With Inadequate Responses to PD-1/PD-L1 Checkpoint Inhibitors in Metastatic or Locally Advanced Malignancies"
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct: {"date": "2026-10-09", "type": "ACTUAL"}

{'armGroupLabels': ['Arm 1 Part 1 Dose Escalation', 'Arm 1 Part 2 Dose Expansion', 'Arm 2 Part 1 Dose Escalation', 'Arm 2 Part 2 Dose Expansion'], 'description': 'IV infusion every 2 weeks', 'name': 'CTX-471', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Arm 2 Part 1 Dose Escalation', 'Arm 2 Part 2 Dose Expansion'], 'description': 'IV infusion every 6 weeks', 'name': 'Pembrolizumab (KEYTRUDA®)', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.